4-methoxy pyrrole derivatives or salts thereof and pharmaceutical composition comprising the same

1. A compound represented by the following Chemical Formula 1 or a pharmaceutically acceptable salt thereof:

in Chemical Formula 1,

R 1 , R 2 and R 3 are each independently hydrogen or halogen, with the proviso that R 1 , R 2 and R 3 cannot be hydrogen simultaneously, and

R 4 and R 5 are each independently hydrogen, halogen, C 1-4 alkyl, C 1-4 alkoxy, C 1-4 haloalkyl, or C 1-4 haloalkoxy, with the proviso that R 4 and R 5 cannot be hydrogen simultaneously.

2. The compound or a pharmaceutically acceptable salt thereof according to claim 1 , wherein R 1 , R 2 and R 3 are each independently hydrogen, fluoro, or chloro, with the proviso that R 1 , R 2 and R 3 cannot be hydrogen simultaneously.

3. The compound or a pharmaceutically acceptable salt thereof according to claim 1 , wherein R 4 and R 5 are each independently hydrogen, chloro, fluoro, methyl, trifluoromethyl, methoxy, or difluoromethoxy, with the proviso that R 4 and R 5 cannot be hydrogen simultaneously.

4. The compound or a pharmaceutically acceptable salt thereof according to claim 1 , wherein the compound is represented by the following Chemical Formula 1-1:

in Chemical Formula 1-1,

R 1 to R 5 are as defined in claim 1 .

5. The compound or a pharmaceutically acceptable salt thereof according to claim 4 , wherein R 1 , R 2 and R 3 are each independently hydrogen, fluoro, or chloro, with the proviso that R 1 , R 2 and R 3 cannot be hydrogen simultaneously.

6. The compound or a pharmaceutically acceptable salt thereof according to claim 4 , wherein R 1 is halogen, and R 2 and R 3 are each independently hydrogen, or halogen.

7. The compound or a pharmaceutically acceptable salt thereof according to claim 4 , wherein R 1 is fluoro, and R 2 and R 3 are each independently hydrogen, fluoro, or chloro, or R 1 is chloro, and R 2 and R 3 are hydrogen.

8. The compound or a pharmaceutically acceptable salt thereof according to claim 4 , wherein R 4 and R 5 are each independently hydrogen, chloro, fluoro, methyl, trifluoromethyl, methoxy, or difluoromethoxy, with the proviso that R 4 and R 5 cannot be hydrogen simultaneously.

9. The compound or a pharmaceutically acceptable salt thereof according to claim 4 , wherein R 4 is halogen, and R 5 is chloro, fluoro, methyl, trifluoromethyl, methoxy, or difluoromethoxy, or R 4 and R 5 are each independently chloro, or fluoro.

10. The compound or a pharmaceutically acceptable salt thereof according to claim 4 , wherein R 1 is fluoro, and R 2 and R 3 are each independently hydrogen, or fluoro, R 4 is hydrogen, and R 5 is chloro, or trifluoromethyl.

11. The compound or a pharmaceutically acceptable salt thereof according to claim 1 , wherein the compound is selected from the group represented by the following Chemical Formulae 1-2 to 1-4:

in Chemical Formulae 1-2 to 1-4,

R 1 to R 5 are as defined in claim 1 .

12. The compound or a pharmaceutically acceptable salt thereof according to claim 1 , wherein the compound is selected from the group consisting of the following compounds:

1) 1-(5-(2-fluorophenyl)-4-methoxy-1-((3-chlorophenyl)sulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine;

2) 1-(5-(2-fluorophenyl)-4-methoxy-1-((3-(trifluoromethyl)phenyl)sulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine;

3) 1-(5-(2-fluorophenyl)-4-methoxy-1-((3-methoxyphenyl)sulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine;

4) 1-(5-(2-fluorophenyl)-4-methoxy-1-((3-difluoromethoxyphenyl)sulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine;

5) 1-(5-(2-chlorophenyl)-4-methoxy-1-((3-methoxyphenyl)sulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine;

6) 1-(5-(2-fluoro-4-chlorophenyl)-4-methoxy-1-((3-chlorophenyl)sulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine;

7) 1-(5-(2-fluoro-4-chlorophenyl)-4-methoxy-1-((3-(trifluoromethyl)phenyl)sulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine;

8) 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methyoxy-1H-pyrrol-3-yl)-N-methylmethanamine;

9) 1-(5-(2,4-difluorophenyl)-1-((3-(trifluoromethyl)phenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine;

10) 1-(5-(2,4-difluorophenyl)-1-((3-methylphenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine;

11) 1-(5-(2,4-difluorophenyl)-1-((3-methoxyphenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine;

12) 1-(5-(2,4-difluorophenyl)-1-((3-difluoromethoxyphenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine;

13) 1-(5-(2,6-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine;

14) 1-(5-(2,6-difluorophenyl)-1-((3-chlorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine;

15) 1-(5-(2,6-difluorophenyl)-1-((3-(trifluoromethyl)phenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine;

16) 1-(5-(2,6-difluorophenyl)-1-((3-methylphenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine;

17) 1-(5-(2,6-difluorophenyl)-1-((3-methoxyphenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine;

18) 1-(5-(2,6-difluorophenyl)-1-((3-chloro-4-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine;

19) 1-(5-(2,6-difluorophenyl)-1-((3,4-difluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine;

20) 1-(5-(2-fluoro-6-chlorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine;

21) 1-(5-(2-fluoro-6-chlorophenyl)-1-((3-chlorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine;

22) 1-(1-((3-fluorophenyl)sulfonyl)-4-methoxy-5-(2,4,6-trifluorophenyl)-1H-pyrrol-3-yl)-N-methylmethanamine;

23) 1-(1-((3-chlorophenyl)sulfonyl)-4-methoxy-5-(2,4,6-trifluorophenyl)-1H-pyrrol-3-yl)-N-methylmethanamine;

24) 1-(1-((3-trifluoromethylphenyl)sulfonyl)-4-methoxy-5-(2,4,6-trifluorophenyl)-1H-pyrrol-3-yl)-N-methylmethanamine;

25) 1-(1-((3-methoxyphenyl)sulfonyl)-4-methoxy-5-(2,4,6-trifluorophenyl)-1H-pyrrol-3-yl)-N-methylmethanamine;

26) 1-(1-((3,4-difluorophenyl)sulfonyl)-4-methoxy-5-(2,4,6-trifluorophenyl)-1H-pyrrol-3-yl)-N-methanamine;

27) 1-(1-((3-fluorophenyl)sulfonyl)-4-methoxy-5-(2,3,6-trifluorophenyl)-1H-pyrrol-3-yl)-N-methylmethanamine;

28) 1-(1-((3-chlorophenyl)sulfonyl)-4-methoxy-5-(2,3,6-trifluorophenyl)-1H-pyrrol-3-yl)-N-methylmethanamine;

29) 1-(1-((3-trifluoromethylphenyl)sulfonyl)-4-methoxy-5-(2,3,6-trifluorophenyl)-1H-pyrrol-3-yl)-N-methylmethanamine;

30) 1-(1-((3-methoxyphenyl)sulfonyl)-4-methoxy-5-(2,3,6-trifluorophenyl)-1H-pyrrol-3-yl)-N-methylmethanamine;

31) 1-(5-(2,5-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine;

32) 1-(5-(2,5-difluorophenyl)-1-((3-trifluoromethylphenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine; and

33) 1-(5-(2,5-difluorophenyl)-1-((3-methoxyphenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine.

13. The compound or a pharmaceutically acceptable salt thereof according to claim 1 , wherein the pharmaceutically acceptable salt is hydrochloride or fumarate salt.

14. A pharmaceutical composition for the treatment of gastrointestinal damage due to gastrointestinal tract ulcer, gastritis, reflux esophagitis or H. pylori , comprising the compound or the pharmaceutically acceptable salt thereof according to claim 1 .

15. A pharmaceutical composition for the treatment of 5-HT receptor-mediated or muscarinic acetylcholine receptor-mediated diseases, comprising the compound or the pharmaceutically acceptable salt thereof according to claim 1 .

16. The pharmaceutical composition according to claim 15 , wherein the 5-HT receptor-mediated or muscarinic acetylcholine receptor-mediated diseases are depression, manic depression, schizophrenia, autism, obsessive-compulsive neurosis, anxiety disorder, migraine, hypertension, eating disorder, irritable bowel syndrome (IBS), peptic ulcer, diabetic neuropathy, asthma, and overactive bladder.